Johnson & Johnson, US4781601046

Johnson & Johnson stock: CAPLYTA filing seeks bipolar mania use

Published on 11/19/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson filed for a fifth CAPLYTA use in bipolar mania after two positive Phase 3 studies. Its stock traded at 242.13 euros on Lang & Schwarz at 17:07 CET.

CAPLYTA filing expands treatment potential

  • Johnson & Johnson submitted a supplemental FDA application for CAPLYTA in bipolar I mania.
  • Two Phase 3 studies reported significant symptom improvement against placebo as early as Day 3.
  • If approved, bipolar mania would become CAPLYTA's fifth approved adult use.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock traded at 242.13 euros on Lang & Schwarz at 17:07 CET on Thursday, November 19, 2026, 3.71 percent below the Xetra close of Wednesday, November 18, at 251.45 euros. The company also submitted a supplemental application seeking U.S. approval for CAPLYTA in bipolar I mania.

Johnson & Johnson announced the filing on November 19 in a PR Newswire release. The submission covers manic or mixed episodes associated with bipolar I disorder in adults, an indication for which CAPLYTA is not currently approved.

Two Phase 3 studies support filing

The application relies on Study 451 and Study 452, randomized, double-blind, placebo-controlled Phase 3 trials testing once-daily CAPLYTA at 42 milligrams. Johnson & Johnson said both studies met their primary and key secondary endpoints.

Manic symptoms improved significantly against placebo as early as Day 3, after two days of treatment, with the improvement sustained through Week 3. The company also reported low discontinuation rates and a safety profile consistent with earlier studies.

CAPLYTA is already approved for bipolar depression, schizophrenia and adjunctive treatment of major depressive disorder in adults. If the FDA grants the new application, bipolar mania would become the medicine's fifth approved adult use, broadening the commercial scope of Johnson & Johnson's Innovative Medicine portfolio.

Johnson & Johnson stock details

  • Company: Johnson & Johnson
  • ISIN: US4781601046
  • Home ticker: JNJ
  • Home exchange: New York Stock Exchange
  • Lang & Schwarz quote: 242.13 euros at 17:07 CET on November 19, 2026
  • Xetra close: 251.45 euros on November 18, 2026

U.S. market conditions remain relevant for healthcare shares; see Current market reports.

More news and analyses on Johnson & Johnson stock.

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70536866 | bgmi